EGFR is an inclusion eligibility criterion in 1 clinical trial for primitive neuroectodermal tumor, of which 0 are open and 1 is closed. Of the trial that contains EGFR status and primitive neuroectodermal tumor as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

ERBB2 is an inclusion eligibility criterion in 1 clinical trial for primitive neuroectodermal tumor, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 status and primitive neuroectodermal tumor as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

ERBB4 is an inclusion eligibility criterion in 1 clinical trial for primitive neuroectodermal tumor, of which 0 are open and 1 is closed. Of the trial that contains ERBB4 status and primitive neuroectodermal tumor as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

EWSR1 is an inclusion eligibility criterion in 1 clinical trial for primitive neuroectodermal tumor, of which 1 is open and 0 are closed. Of the trial that contains EWSR1 status and primitive neuroectodermal tumor as inclusion criteria, 1 is phase 1 (1 open) [3].

FUS is an inclusion eligibility criterion in 1 clinical trial for primitive neuroectodermal tumor, of which 1 is open and 0 are closed. Of the trial that contains FUS status and primitive neuroectodermal tumor as inclusion criteria, 1 is phase 1 (1 open) [3].

H3F3A is an inclusion eligibility criterion in 2 clinical trials for primitive neuroectodermal tumor, of which 2 are open and 0 are closed. Of the trials that contain H3F3A status and primitive neuroectodermal tumor as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].